Skip to content

Methylphenidate and the pathogenesis of apathy in dementia

Methylphenidate and the pathogenesis of apathy in dementia - Methylphenidate and apathy

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON30740
Enrollment
37
Registered
2007-07-03
Start date
2007-12-12
Completion date
Unknown
Last updated
2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lack of initiative

Interventions

All subjects receive a methylphenidate challenge task or a placebo condition. All subjects will receive a dose of 10 mg methylphenidate in the challenge condition.

Sponsors

Universiteit Maastricht
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: -Dementia diagnosed according to the DSM-IV criteria for dementia -Presence of a reliable informant -Presence of apathy -Capable to consent -Informed consent

Exclusion criteria

Exclusion criteria: -If living in a nursing home at the start of the study -Patients without a reliable informant -Concurrent psychiatric disease -Presence of agitation, irritability, and/or psychotic symptoms -Use of pharmacological medication -Use of vasopressors -Abuse of alcohol and drugs

Design outcomes

Primary

MeasureTime frame
Change in apathy score after the methylphenidate challenge (difference between before and after the challenge) compared to the change in score after the placebo condition as measured by the patient version of the Apathy Inventory (IA)

Secondary

MeasureTime frame
Change in cognitive and other behavioural scores after the methylphenidate challenge (difference between before and after the challenge) compared to the change in score after the placebo condition * on the level of frontal related behaviour, as assessed by specific frontal related neuropsychological tests like the Verbal Fluency Test, the Stroop Colour Word Test and five tasks of the CANTAB. * on the level of novelty seeking behaviour as assessed by a 15 minute observation of the patient.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)